Titre : Récepteur facteur neurotrophique ciliaire

Récepteur facteur neurotrophique ciliaire : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cholangitis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Récepteur facteur neurotrophique ciliaire : Questions médicales les plus fréquentes", "headline": "Récepteur facteur neurotrophique ciliaire : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Récepteur facteur neurotrophique ciliaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-06", "dateModified": "2025-04-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Récepteur facteur neurotrophique ciliaire" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Récepteurs facteur croissance nerf", "url": "https://questionsmedicales.fr/mesh/D017475", "about": { "@type": "MedicalCondition", "name": "Récepteurs facteur croissance nerf", "code": { "@type": "MedicalCode", "code": "D017475", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.750.400.550" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Sous-unité alpha du récepteur du facteur neurotrophique ciliaire", "alternateName": "Ciliary Neurotrophic Factor Receptor alpha Subunit", "url": "https://questionsmedicales.fr/mesh/D053739", "about": { "@type": "MedicalCondition", "name": "Sous-unité alpha du récepteur du facteur neurotrophique ciliaire", "code": { "@type": "MedicalCode", "code": "D053739", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.750.400.550.250.249" } } }, { "@type": "MedicalWebPage", "name": "Récepteur gp130 de cytokines", "alternateName": "Cytokine Receptor gp130", "url": "https://questionsmedicales.fr/mesh/D050822", "about": { "@type": "MedicalCondition", "name": "Récepteur gp130 de cytokines", "code": { "@type": "MedicalCode", "code": "D050822", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.750.400.550.250.500" } } }, { "@type": "MedicalWebPage", "name": "Sous-unité alpha du récepteur au facteur d'inhibition de la leucémie", "alternateName": "Leukemia Inhibitory Factor Receptor alpha Subunit", "url": "https://questionsmedicales.fr/mesh/D053680", "about": { "@type": "MedicalCondition", "name": "Sous-unité alpha du récepteur au facteur d'inhibition de la leucémie", "code": { "@type": "MedicalCode", "code": "D053680", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.750.400.550.250.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Récepteur facteur neurotrophique ciliaire", "alternateName": "Receptor, Ciliary Neurotrophic Factor", "code": { "@type": "MedicalCode", "code": "D020801", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Giovanni Tossetta", "url": "https://questionsmedicales.fr/author/Giovanni%20Tossetta", "affiliation": { "@type": "Organization", "name": "Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy." } }, { "@type": "Person", "name": "Antonio Giordano", "url": "https://questionsmedicales.fr/author/Antonio%20Giordano", "affiliation": { "@type": "Organization", "name": "Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy." } }, { "@type": "Person", "name": "Cuihong Jia", "url": "https://questionsmedicales.fr/author/Cuihong%20Jia", "affiliation": { "@type": "Organization", "name": "Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA. Electronic address: jiac01@etsu.edu." } }, { "@type": "Person", "name": "Theo Hagg", "url": "https://questionsmedicales.fr/author/Theo%20Hagg", "affiliation": { "@type": "Organization", "name": "Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA." } }, { "@type": "Person", "name": "Jessica Perugini", "url": "https://questionsmedicales.fr/author/Jessica%20Perugini", "affiliation": { "@type": "Organization", "name": "Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Lipocalin2 as a useful biomarker for risk stratification in patients with acute cholangitis: A single-center prospective and observational study.", "datePublished": "2022-05-28", "url": "https://questionsmedicales.fr/article/35640670", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cca.2022.05.022" } }, { "@type": "ScholarlyArticle", "name": "Efficacy of ultrasound-guided percutaneous transhepatic biliary drainage for acute obstructive suppurative cholangitis combined with septic shock.", "datePublished": "2023-07-29", "url": "https://questionsmedicales.fr/article/37523978", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clinsp.2023.100258" } }, { "@type": "ScholarlyArticle", "name": "Immune thrombocytopenic purpura in primary biliary cholangitis and localized cutaneous systemic sclerosis: case report and literature review.", "datePublished": "2023-03-04", "url": "https://questionsmedicales.fr/article/36870017", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12328-023-01776-z" } }, { "@type": "ScholarlyArticle", "name": "Outcomes and predictors of delayed endoscopic biliary drainage for severe acute cholangitis due to choledocholithiasis in an intensive care unit.", "datePublished": "2023-02-24", "url": "https://questionsmedicales.fr/article/36842843", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.dld.2023.01.158" } }, { "@type": "ScholarlyArticle", "name": "Validation of Tokyo guidelines 2018 for safety and mortality benefit from urgent ERCP in acute cholangitis across different age groups.", "datePublished": "2022-12-20", "url": "https://questionsmedicales.fr/article/36399089", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jhbp.1275" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Récepteurs de surface cellulaire", "item": "https://questionsmedicales.fr/mesh/D011956" }, { "@type": "ListItem", "position": 6, "name": "Récepteurs peptidiques", "item": "https://questionsmedicales.fr/mesh/D018000" }, { "@type": "ListItem", "position": 7, "name": "Récepteur facteur croissance", "item": "https://questionsmedicales.fr/mesh/D017978" }, { "@type": "ListItem", "position": 8, "name": "Récepteurs facteur croissance nerf", "item": "https://questionsmedicales.fr/mesh/D017475" }, { "@type": "ListItem", "position": 9, "name": "Récepteur facteur neurotrophique ciliaire", "item": "https://questionsmedicales.fr/mesh/D020801" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Récepteur facteur neurotrophique ciliaire - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Récepteur facteur neurotrophique ciliaire", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Récepteur facteur neurotrophique ciliaire", "description": "Comment diagnostiquer une dysfonction du récepteur CNTF ?\nQuels examens sont utilisés pour évaluer le récepteur CNTF ?\nY a-t-il des biomarqueurs pour le récepteur CNTF ?\nLe diagnostic nécessite-t-il une biopsie ?\nQuels symptômes peuvent indiquer un problème avec le CNTF ?", "url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=8#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Récepteur facteur neurotrophique ciliaire", "description": "Quels sont les symptômes d'une déficience en CNTF ?\nLa douleur neuropathique est-elle liée au CNTF ?\nPeut-on observer des troubles moteurs avec le CNTF ?\nLes troubles sensoriels sont-ils associés au CNTF ?\nY a-t-il des signes cliniques spécifiques au CNTF ?", "url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=8#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Récepteur facteur neurotrophique ciliaire", "description": "Peut-on prévenir les troubles liés au CNTF ?\nY a-t-il des mesures préventives spécifiques ?\nL'exercice régulier aide-t-il à prévenir les troubles du CNTF ?\nUne alimentation équilibrée peut-elle aider ?\nLe stress a-t-il un impact sur le CNTF ?", "url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=8#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Récepteur facteur neurotrophique ciliaire", "description": "Quels traitements sont disponibles pour les troubles du CNTF ?\nLes thérapies géniques peuvent-elles aider le CNTF ?\nLes médicaments anti-inflammatoires sont-ils efficaces ?\nLa physiothérapie est-elle recommandée ?\nY a-t-il des traitements expérimentaux pour le CNTF ?", "url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=8#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Récepteur facteur neurotrophique ciliaire", "description": "Quelles complications peuvent survenir avec le CNTF ?\nLe CNTF peut-il entraîner des troubles cognitifs ?\nY a-t-il un risque de dépendance aux médicaments ?\nLes complications sont-elles réversibles ?\nLe CNTF peut-il affecter la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=8#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Récepteur facteur neurotrophique ciliaire", "description": "Quels sont les facteurs de risque pour les troubles du CNTF ?\nL'âge est-il un facteur de risque pour le CNTF ?\nLe sexe influence-t-il le risque de troubles du CNTF ?\nLes infections peuvent-elles augmenter le risque ?\nLe mode de vie influence-t-il le risque de troubles ?", "url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=8#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction du récepteur CNTF ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests neurologiques et des analyses génétiques." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer le récepteur CNTF ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des IRM et des électromyogrammes peuvent être utilisés pour évaluer la fonction nerveuse." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs pour le récepteur CNTF ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de biomarqueurs spécifiques pour le récepteur CNTF." } }, { "@type": "Question", "name": "Le diagnostic nécessite-t-il une biopsie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Une biopsie n'est généralement pas nécessaire pour diagnostiquer les troubles liés au CNTF." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec le CNTF ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la faiblesse musculaire ou des douleurs neuropathiques peuvent indiquer un problème." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en CNTF ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent faiblesse musculaire, douleurs chroniques et troubles sensoriels." } }, { "@type": "Question", "name": "La douleur neuropathique est-elle liée au CNTF ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le CNTF joue un rôle dans la modulation de la douleur neuropathique." } }, { "@type": "Question", "name": "Peut-on observer des troubles moteurs avec le CNTF ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles moteurs peuvent survenir en raison d'une dysfonction du CNTF." } }, { "@type": "Question", "name": "Les troubles sensoriels sont-ils associés au CNTF ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles sensoriels peuvent être observés en cas de dysfonction du CNTF." } }, { "@type": "Question", "name": "Y a-t-il des signes cliniques spécifiques au CNTF ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'hypersensibilité ou l'engourdissement peuvent être spécifiques." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles liés au CNTF ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives spécifiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les traumatismes nerveux et gérer les maladies chroniques peut aider." } }, { "@type": "Question", "name": "L'exercice régulier aide-t-il à prévenir les troubles du CNTF ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut renforcer les muscles et améliorer la santé nerveuse." } }, { "@type": "Question", "name": "Une alimentation équilibrée peut-elle aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en nutriments favorise la santé nerveuse et musculaire." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur le CNTF ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affecter la fonction nerveuse et aggraver les symptômes." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les troubles du CNTF ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des thérapies médicamenteuses et des interventions physiques." } }, { "@type": "Question", "name": "Les thérapies géniques peuvent-elles aider le CNTF ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours sur l'utilisation de thérapies géniques pour cibler le CNTF." } }, { "@type": "Question", "name": "Les médicaments anti-inflammatoires sont-ils efficaces ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent réduire l'inflammation et améliorer les symptômes liés au CNTF." } }, { "@type": "Question", "name": "La physiothérapie est-elle recommandée ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la physiothérapie peut aider à améliorer la fonction musculaire et réduire la douleur." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux pour le CNTF ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements expérimentaux, comme les thérapies biologiques, sont en cours d'évaluation." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le CNTF ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent la progression des troubles neurologiques et la douleur chronique." } }, { "@type": "Question", "name": "Le CNTF peut-il entraîner des troubles cognitifs ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles cognitifs peuvent survenir en raison de la dysfonction du CNTF." } }, { "@type": "Question", "name": "Y a-t-il un risque de dépendance aux médicaments ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains traitements peuvent entraîner une dépendance, nécessitant une surveillance." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié." } }, { "@type": "Question", "name": "Le CNTF peut-il affecter la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les troubles liés au CNTF peuvent significativement affecter la qualité de vie." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les troubles du CNTF ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des maladies auto-immunes et des traumatismes." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour le CNTF ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de troubles liés au CNTF augmente avec l'âge." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque de troubles du CNTF ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines études montrent que le sexe peut influencer le risque de troubles." } }, { "@type": "Question", "name": "Les infections peuvent-elles augmenter le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections peuvent déclencher des troubles liés au CNTF." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque de troubles ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque." } } ] } ] }

Sources (884 au total)

Lipocalin2 as a useful biomarker for risk stratification in patients with acute cholangitis: A single-center prospective and observational study.

Lipocalin2 (LCN2) is being increasingly used to diagnose and predict severe bacterial infection. We aimed to evaluate the predictive value of serum lipocalin 2 for severity grading of acute cholangiti... A total of 108 patients were enrolled in this study. Blood samples were obtained at admission. Receiver operating characteristic (ROC) curves were built to assess the abilities of LCN2 levels to predi... The levels of LCN2 on admission increased significantly with the severity of AC. By analysis of ROC curve of biomarkers for differentiating patients with moderate to severe AC (versus mild AC), the AU... Serum LCN2 concentration on patient admission could better predict severe acute cholangitis than WBC, CRP, PCT and NLR. Serum LCN2 may become a potential biomarker in the risk stratification of acute ...

Efficacy of ultrasound-guided percutaneous transhepatic biliary drainage for acute obstructive suppurative cholangitis combined with septic shock.

This study aimed to investigate the efficacy of ultrasound-guided Percutaneous Transhepatic Biliary Drainage (PTCD) for the treatment of Acute Obstructive Suppurative Cholangitis (AOSC) combined with ... Clinical data of 86 patients with AOSC and septic shock admitted to our hospital between January 2019 and May 2021 were retrospectively analyzed and grouped according to different treatment methods. A... The total effective rate in the SG (88.37%) was higher than that in the CNG (69.77%) (p < 0.05); after surgery, the serum inflammatory factors PCT, IL-6, TNF-α, CRP levels, liver function indicators s... Ultrasound-guided PTCD for AOSC combined with septic shock can facilitate the recovery of liver and immune functions with a low complication rate....

Immune thrombocytopenic purpura in primary biliary cholangitis and localized cutaneous systemic sclerosis: case report and literature review.

Primary biliary cholangitis (PBC) is a chronic progressive cholestatic liver disease of uncertain etiology. Although PBC is frequently complicated by Sjögren's syndrome and chronic thyroiditis, it can...

Outcomes and predictors of delayed endoscopic biliary drainage for severe acute cholangitis due to choledocholithiasis in an intensive care unit.

Acute cholangitis (AC) is an infection of the biliary tract secondary to biliary obstruction requiring biliary drainage through endoscopic retrograde cholangiopancreatography. This study aims to compa... Patient with severe AC due to choledocholithiasis admitted to intensive care unit were included. Early ERCP was defined was as ERCP performed within 24 h following hospital admission. Propensity-score... The delayed ERCP group had a higher mortality rate at 30 days (45,5 versus 13%, <0.001) and at 1 year (59,7% versus 15,6%, p <0.001). Delayed ERCP had also a higher rate of respiratory adverse events ... Delays in ERCP for patients with severe AC appear to be associated with higher mortality rate and prolonged ICU and hospital stays....

Validation of Tokyo guidelines 2018 for safety and mortality benefit from urgent ERCP in acute cholangitis across different age groups.

The 2018 Tokyo Guidelines (TG18) recommend urgent endoscopic biliary drainage based on acute cholangitis (AC) severity. Therefore, we evaluated the safety and mortality benefits of urgent endoscopic r... Using International Classification of Diseases-10 (ICD-10) codes, we sampled adult AC patients from National Inpatient Sample. TG18 definition of cholangitis severity was used to identify patients wit... Among 137 100 patients, there were 93 365 (68.09%) patients with nonsevere cholangitis and 43 735 (31.91%) patients with severe cholangitis. Urgent ERCP (within 24 h) resulted in decreased mortality i... This study demonstrates the mortality benefit from urgent ERCP for AC in different age groups and describes the safety of performing urgent ERCP in patients of various ages. Therefore, we recommend th...

Differential immune response to xenobiotic-modified self-molecule in simple and connective tissue disease-associated primary biliary cholangitis.

Our previous studies demonstrated that 2-octynoic acid (2OA) might alter the conformational structure of the inner lipoic acid (LA) binding domain (ILD) in the E2 subunit of pyruvate dehydrogenase com... Intein-mediated protein ligation was used to prepare ILD, LA-ILD and 2OA-ILD, and their reactivity with serum samples from 124 S-PBC and 132 CTD-PBC patients was examined. The antibodies to LA, 2OA, L... Both the percentage and reactivity of antibody to 2OA in S-PBC were significantly higher than in CTD-PBC. Antibodies to 2OA and to LA between the two groups separately shared the same characteristics.... Xenobiotic 2OA might play less important pathogenic role in CTD-PBC than in S-PBC, suggesting that different underlying mechanisms are involved in their immune intolerance to PDC-E2....

Comparison of short-course antibiotic therapy of 6 or less days with a longer treatment in patients with cholangitis after liver transplantation.

Stenosis of the biliary anastomosis predisposes liver graft recipients to bacterial cholangitis. Antibiotic therapy (AT) is performed according to individual clinical judgment, but duration of AT rema... All liver graft recipients with acute cholangitis according to the Tokyo criteria grade 1 and 2 after endoscopic retrograde cholangiography (ERC) were included. Outcome of patients treated with short ... In total, 30 patients were included with a median of 313 (range 34-9849) days after liver transplantation until first proven cholangitis. Among 62 cases in total, 51/62 (82%) were graded as Tokyo-1 an... A shorter antibiotic course than 7 days shows good results in selected, ERC-treated patients for post-transplantation biliary strictures....

Risk factors for postoperative cholangitis after pancreaticoduodenectomy and evaluation of internal stenting on hepaticojejunostomy: A single-center propensity score-based analysis.

This retrospective study aimed to investigate the risk factors for postoperative cholangitis (POC) after pancreaticoduodenectomy (PD) and the efficacy of stenting on hepaticojejunostomy (HJ).... We investigated 162 patients. Postoperative cholangitis occurring before and after discharge was defined as early-onset POC (E-POC) and late-onset POC (L-POC), respectively. Risk factors for E-POC and... Body mass index (BMI) ≥ 25 kg/m... BMI ≥ 25 kg/m...

Primary exploring the value of metagenomic next-generation sequencing in detecting pathogenic bacteria of cholangitis with biliary atresia after Kasai operation.

To evaluate the value of metagenomic next-generation sequencing (mNGS) in detecting pathogenic bacteria of cholangitis for patients with biliary atresia after Kasai operation.... This study retrospectively analyzed patients of biliary atresia with cholangitis after Kasai operation who were admitted to Xi'an Children's Hospital from July 2019 to December 2021. Both blood cultur... This study included total of 30 cholangitis occurred in 25 patients. There were significant differences in the detection rate of pathogenic bacteria [23.3 vs.73.3%, P < 0.05] and the test time [120 (1... Comparing with traditional blood culture, mNGS is more efficient, convenient and accurate in the detection of pathogens. It provides a new method for accurately detecting pathogenic bacteria of cholan...

Galectin-3 and prohibitin 1 are autoantigens in IgG4-related cholangitis without clear-cut protective effects against toxic bile acids.

IgG4-related cholangitis (IRC) is the hepatobiliary manifestation of IgG4-related disease, a systemic B cell-driven fibro-inflammatory disorder. Four autoantigens have recently been described in IgG4-... Anti-galectin-3, anti-prohibitin 1 and 2 autoantibody positivity in IRC and healthy and disease (primary sclerosing cholangitis (PSC)) control sera was assessed by ELISA/liquid chromatography-tandem m... Anti-galectin-3 autoantibodies were detected in 13.5% of individuals with IRC but not in PSC. Knockdown of... A subset of individuals with IRC have autoantibodies against galectin-3 and prohibitin 1. Gene-specific knockdown, pharmacological inhibition, and recombinant protein substitution did not clearly disc...